Table 7.
COVID-19 outcomes in subgroup (b/tsDMARDs vs. only conventional DMARDs use) in RA with COVID-19 cohort before and after propensity matching (COVID-19 diagnosis anytime between January 20, 2020 and April 11, 2021).
| Outcome | Before Propensity Matching | After Propensity Matching | ||||||
|---|---|---|---|---|---|---|---|---|
| RA with COVID-19 with b/tsDMARDs† (n = 1,346) | RA with COVID-19 with cDMARDs‡ (n = 2,819) | Risk ratio (95% CI) |
P value | RA with COVID-19 with b/tsDMARDs† (n = 1,337) | RA with COVID-19 with cDMARDs‡ (n = 1,337) |
Risk ratio (95% CI) |
P value | |
| Mortality | 46 3.42% |
119 4.22% |
0.81 (0.58, 1.13) |
0.2136 | 46 (3.44%) |
43 3.216% |
1.07 (0.71, 1.61) |
0.7464 |
| Hospitalization | 289 21.47% |
678 24.05% |
0.89 (0.79, 1.01) |
0.0651 | 289 (21.62%) |
289 21.616% |
1.00 (0.87, 1.16) |
1.0000 |
| ICU admission | 68 5.05% |
144 5.11% |
0.99 (0.75, 1.31) |
0.9385 | 68 (5.09%) |
62 4.637% |
1.10 (0.78, 1.53) |
0.5895 |
| Mechanical ventilation | 46 3.42% |
87 3.09% |
1.11 (0.78, 1.57) |
0.5695 | 46 (3.44%) |
38 2.842% |
1.21 (0.79, 1.85) |
0.3751 |
| Severe COVID-19§ | 68 5.05% |
169 6.00% |
0.84 (0.64, 1.11) |
0.2192 | 68 (5.09%) |
65 4.862% |
1.05 (0.75, 1.46) |
0.7896 |
| Acute kidney injury | 93 6.91% |
207 7.34% |
0.94 (0.74, 1.19) |
0.6127 | 93 (6.96%) |
80 5.984% |
1.16 (0.87, 1.55) |
0.3068 |
| KRT/Hemodialysis | 10 0.75% |
10 0.36% |
2.08 (0.87, 4.98) |
0.0935 | 10 (0.76%) |
10 0.755% |
1.00 (0.42, 2.40) |
0.9973 |
| ARDS | 40 2.97% |
56 1.99% |
1.50 (1.00, 2.23) |
0.0475 | 40 (2.99%) |
32 2.393% |
1.25 (0.79, 1.98) |
0.3392 |
| Ischemic Stroke | 16 1.19% |
37 1.31% |
0.91 (0.51, 1.62) |
0.7388 | 16 (1.20%) |
13 0.972% |
1.23 (0.59, 2.55) |
0.5754 |
| VTE | 53 3.94% |
107 3.80% |
1.04 (0.75, 1.43) |
0.8236 | 53 (3.96%) |
52 (3.89%) |
1.02 (0.70, 1.48) |
0.9207 |
| Sepsis | 79 5.87% |
164 5.82% |
1.01 (0.78, 1.31) |
0.9470 | 78 5.834% |
65 4.862% |
1.20 (0.87, 1.65) |
0.2638 |
Age, sex, race, body mass index, and comorbidities (hypertension, chronic lower lung disease, diabetes mellitus, ischemic heart disease, chronic kidney disease, heart failure, cerebrovascular disease, nicotine dependence, and alcohol-related disorders) were included as covariates in propensity score matching. DMARDs disease-modifying antirheumatic drugs, ICU Intensive care unit, KRT Kidney replacement therapy, ARDS Acute respiratory distress syndrome, VTE Venous thromboembolism.
† Either biologic/targeted synthetic DMARDs monotherapy, or combination with cDMARDs. b/ts DMARDs included adalimumab, etanercept, infliximab, golimumab, certolizumab, tocilizumab, sarilumab, rituximab, upadacitinib, tofacitinib, baricitinib, abatacept.
‡ Only conventional DMARDs use (without combination with b/ts DMARDs). cDMARDs included methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine.
§ Composite of mechanical ventilation and mortality.